← Back to headlines
Merck Strikes Nearly $6 Billion Deal for Cancer Biotech Terns
Merck has reached an agreement to acquire cancer biotech firm Terns in a deal valued at nearly $6 billion, expanding its portfolio in the oncology sector.
25 Mar, 13:14 — 25 Mar, 13:14
Sources
Showing 1 of 1 sources
